Back to Stakeholders
Research, Drug Development & ManufacturingLead program: Pre-clinical
Lobe SciencesCSE: LOBE
1 Drug Candidate1 Trial
Canadian psychedelic biotech developing conjugated psilocin formulations for treatment-resistant conditions. Spun out its proprietary Conjugated Psilocin™ technology to Cynaptec Pharmaceuticals in April 2025 via an $8.46 million financing round. Lead programme L-130 targets cluster headache disorder.
Drug Pipeline
1L-130
Pre-clinical
Conjugated Psilocin™ formulation targeting cluster headache disorder. Technology spun out to Cynaptec Pharmaceuticals April 2025 with $8.46M financing.
Quick Facts
- Type
- Public Biotech
- Ticker
- CSE: LOBE
- Lead Stage
- Pre-clinical
- Website
- Visit